Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
Interleukin-34 (IL-34) was identified through a functional screening of a library of secreted proteins after transfection of an embryonic kidney cell line with recombinant cDNAs. Flow cytometry and monocyte viability assays demonstrated increased survival and/or proliferation of monocytes induced by IL-34 and specific binding of IL-34 to CD14+ monocytes. IL-34 is a second ligand to the colony stimulating factor (CSF)-1 receptor in addition to CSF1. Like CSF1, IL-34 stimulates phosphorylation of ERK1 and ERK2 in human monocytes and induces differentiation of bone marrow cells into macrophages. Despite its predicted molecular weight, IL-34 will often run at higher molecular weight in SDS-PAGE.
Related Pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis of IL-34 in human brain tissue lysate with IL-34 antibody at 0.25 µg/ml in (A) the absence and (B) the presence of blocking peptide.
Researchers who bought this antibody have also purchased:
